Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'This Isn't The Past Novartis,' Jimenez Tells JPM Conference

This article was originally published in Scrip

Executive Summary

Novartis AG is making faster decisions. That's the message CEO Joseph Jimenez wanted investors at the JP Morgan Healthcare conference Jan. 11 to take away. He vowed the company would not spend years investing to turn around its Alcon eye care business before making a decision about considering alternative options for the unit.

You may also be interested in...



Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.

INTERVIEW: Novartis' Oncology Chief On Sharpening Its Competitive Advantage

Novartis Oncology President Bruno Strigini talks about refining the pharma major's oncology strategy and its pipeline potential.

Radius Business Review Ends In Sale To Investment Funds

Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.

Topics

Latest News
UsernamePublicRestriction

Register

SC064188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel